NBIX -Long -TP>25%NASDAQ:NBIX - LONG - RISK 1/5 - TP > 25% We already have a buy position. Good luck to everyone... ==============================Longby stsidx1
NBIX -Long -TP>25%NASDAQ:NBIX -Long -TP>25-30% and more -waiting for a point to enter a long positionLongby stsidx1
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-oLongby olimchik0
Textbook bullish flagIt looks like a beautiful flag (or pennant) to me, with high volume at the pole and the volume drying up during the consolidation. I am expecting continuation. Longby dobisaUpdated 0
(Potential Trade) NBIX(13 May 2024) Disclaimer: All information posted are the author's own trades/potential trades. The author is not a certified Financial Advisor and do not have the certifications to provide financial advice. These information are strictly for educational purposes only and do not constitute any finanLongby ElliotWaveTradesUpdated 0
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th. Investor and trader interest seems to be moderately increasing in the past week. The combined MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket before 7:45 AM Longby AwesomeAvaniUpdated 223
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidatLongby UnknownUnicorn23190992
Neurocrine Biosciences (NBIX: NASDAQ)Neurocrine Biosciences (NBIX), a biotech company specializing in treatments for neurological, endocrine, and psychiatric disorders, is poised for opportunities in congenital adrenal hyperplasia (CAH). Analysts project NBIX to potentially achieve worldwide revenue of $660 million by fiscal year 2030,Longby Richtv_official1
NBIX view(personal)For this stock i have done some deep analysis including looking at the financial reports and estimated points provided by big bank analyst. i have come to the conclusion that after this close below the strong daily support. this pair is likely going to go to the 95 dollar zone within 2 weeks and frNLongby PHANTOMFX_Updated 1
$NBIX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $NBIX after a negative under reaction following its earnings release placing the stock in drift D .Longby EPSMomentum0